Quick Facts: Main Therapeutic Domains

• General Anesthesia: Helps induce and maintain a state of general anesthesia during surgical and medical procedures.
• Procedural Sedation: Assists in achieving a state of monitored sedation for adult patients undergoing certain medical or diagnostic procedures.
• Intensive Care Sedation: Used to provide sedation for mechanically ventilated adult patients in the Intensive Care Unit (ICU).

Propofol is a medication utilized in medical settings to achieve either general anesthesia or a state of sedation. Its primary application is in the induction and maintenance of general anesthesia for patients undergoing surgery. This action helps ensure the patient remains unconscious and unaware during the procedure. The drug is also used to facilitate monitored anesthesia care (MAC) sedation in adults who are undergoing diagnostic or surgical procedures.

Furthermore, this medication provides essential support by providing sedation for intubated, mechanically ventilated adult patients who require intensive care. It is an established option for managing consciousness and relaxation in these critical care scenarios. Propofol is administered intravenously and its use is subject to established clinical guidelines and professional oversight.

Eligibility and Contraindications

Official regulatory documents define strict criteria for who can and cannot use Propofol, primarily focusing on allergies, age, and patient physical status.

Absolute Contraindications (Must Not Use):

• Patients with known hypersensitivity to the active substance (Propofol) or any of the excipients, including known allergies to egg or soy products, as the formulation contains egg lecithin and/or soya-bean oil.

Age and Indication Restrictions:

• Pediatric ICU Sedation: Propofol is contraindicated for use in pediatric patients aged 16 years or younger for sedation in the Intensive Care Unit (ICU).
• General Anesthesia: Use is restricted by minimum age: ge 3 years for induction of anesthesia and ge 2 months for maintenance of anesthesia.

Conditional Use (Restricted Populations):

• Elderly, Debilitated, or ASA Physical Status III/IV patients require restricted use; doses must be significantly lower and administered slowly to minimize the risk of severe cardiorespiratory depression.
• Pregnancy and Lactation: Use during pregnancy is generally not recommended unless absolutely necessary. Breastfeeding women are advised to interrupt nursing and discard breast milk for 24 hours following administration.

Propofol is known to interact with several classes of medications, primarily through effects that lead to additive Central Nervous System (CNS) and cardiorespiratory depression. These interactions often necessitate a dose reduction of Propofol.

Interaction scope

Medicinal product categories with documented interactions:

• Opioids and Sedatives (including Benzodiazepines and Barbiturates)
• Other Analgesic Agents
• Other CNS depressants (e.g., Alcohol, inhalational anesthetic agents)

Specific Interacting Medicines:

• Valproate (Valproic acid)

Interaction Mechanisms and Classifications

• Additive CNS/Cardiorespiratory Depression (Pharmacodynamic): Concomitant use with opioids, sedatives, or other CNS depressants may significantly increase the anesthetic/sedative effects of Propofol. This combination also carries an increased risk of pronounced decreases in blood pressure and cardiac output, and may cause apnea or severe bradycardia (especially in pediatric patients receiving fentanyl).
• Increased Propofol Levels (Pharmacokinetic): The co-administration of Valproate may lead to increased blood levels of Propofol (due to inhibition of propofol metabolism). Therefore, the dose of Propofol must be reduced when administered with Valproate, and patients must be closely monitored for excessive sedation.

The overall interaction profile for Propofol highlights the high risk of additive effects when used with other CNS depressants, requiring mandatory dose adjustment and careful titration by a healthcare professional to ensure patient safety.

Mechanism of Action: Pharmacodynamics

Propofol's primary action involves positive allosteric modulation of the Gamma-aminobutyric acid type A ( GABA A) receptor in the central nervous system (CNS). By binding to specific sites, primarily on the beta subunits, the molecule prolongs the opening of the associated chloride ion ( Cl^-) channel when activated by GABA. This increased influx of Cl^- causes neuronal hyperpolarization, which profoundly suppresses action potential generation.

This widespread neuronal inhibition results in a generalized reduction in CNS activity. A secondary consequence involves the central inhibition of sympathetic nervous system outflow, which reduces the signals for vessel constriction. This mechanism leads to a decrease in systemic vascular resistance and a reduction in cardiac preload, contributing to hypotension. Additionally, the drug induces a coupled reduction in the cerebral metabolic rate for oxygen consumption ( CMRO2) and cerebral blood flow (CBF), which affects intracranial fluid dynamics.

Propofol is administered exclusively as an intravenous (IV) injection or continuous infusion by healthcare professionals and is not indicated for any other route. The medicine is supplied solely as a sterile, oil-in-water injectable emulsion. Dosing is highly individualized and must be titrated to the specific clinical response of the patient, rather than following a fixed schedule. The dosage is unrelated to meal timing or common time-of-day constraints.

For the induction of general anesthesia in healthy adults, the initial dose is typically calculated between 1.5 to 2.5 mg/kg and is administered slowly with continuous assessment. Maintenance is achieved via a continuous infusion into a vein, with specific maintenance rates ranging, for example, from 4 to 12 mg/kg/hour for general anesthesia and 0.3 to 4.0 mg/kg/hour for Intensive Care Unit (ICU) sedation.

Specific adjustments to the regimen are required for certain populations. Older adults and debilitated patients generally require a lower initial dose and a slower rate of administration. Propofol is not recommended for ICU sedation in pediatric patients 16 years of age or younger.

Due to the drug's formulation, strict aseptic technique is mandatory during handling. Administration of the drug from a single-dose vial must be completed within 12 hours of spiking the container; all unused product and administration lines must be discarded after this time limit.

Пропофол: Recent Clinical Evidence

Evidence for General Anesthesia and Sedation in Procedures

Research has extensively explored Propofol in general anesthesia through Randomized Controlled Trials (RCTs) and systematic reviews. Studies monitored the measured time required for both onset of the anesthetic state and return to consciousness after the infusion was discontinued. Findings describe patterns observed in the studies, including those conducted across the general adult population, as well as in older and younger patients. For procedural sedation (Monitored Anesthesia Care, or MAC), studies examined the measured depth of sedation and the time until patients met established discharge criteria. Research highlights that some patients experienced temporary and often transient changes in blood pressure following initial administration.

Evidence for Sedation in Intensive Care

Propofol was also observed in studies for providing continuous sedation for critically ill, mechanically ventilated adults and children in the Intensive Care Unit (ICU). Outcomes monitored included the total duration of mechanical ventilation time and the patient’s overall ICU length of stay (LOS). Research highlights measured differences in ventilation time when Propofol was studied in comparison to some older sedative agents. However, findings were mixed when Propofol was compared against certain newer, non-benzodiazepine sedative alternatives, meaning results did not always show significant differences in outcomes like time on the ventilator.

Special Populations and Research Gaps

Propofol was evaluated in trials specifically involving pediatric patients (children) and older adults (geriatric patients) to explore how symptoms are measured and managed in these groups. Long-term effects are not fully established because the focus of most trials is on the brief periods of general anesthesia or the duration of acute sedation. Data for certain groups remain insufficient, and the certainty of evidence remains low for some long-term outcomes in the critically ill population. Research provides context but not individual predictions, and studies reflect the specific conditions under which they were conducted.

Key Studies & References

1. Propofol Safety in Pediatric Surgery: A Comprehensive Review

Common questions about Пропофол (FAQ)

Q: Why is Propofol sometimes called "milk of amnesia"?

This informal name is widely recognized in clinical discussion due to two factors described in regulatory commentary. Firstly, the medication itself is a sterile, white, milky-looking liquid. Secondly, it quickly causes both reversible unconsciousness (amnesia) and sedation, leading to the nickname "milk of amnesia."

Q: How fast does Propofol start working after injection?

Official product information describes Propofol as having a rapid onset of action. After it is administered intravenously, loss of consciousness typically occurs within 40 seconds. This rapid onset is a characteristic property used for the induction of anesthesia.

Q: Does Propofol cause memory loss after the procedure is over?

The drug's primary effect during administration is to induce temporary amnesia via its action on the central nervous system. Official sources indicate that long-term cognitive effects are not fully established in most adult populations. For children under the age of four, regulatory information highlights the need for caution, especially with prolonged use (over three hours), due to observed neuronal changes.

Q: How does Propofol compare to other types of anesthesia?

Clinical guidelines indicate that Propofol is a widely used and standard agent for anesthesia induction. It is recognized for its favorable properties, particularly a fast clearance rate from the body compared to some older medications. This rapid clearance profile is associated with a quicker recovery time in clinical observations.

Q: Why does Propofol appear white?

Propofol is manufactured as a sterile, oil-in-water injectable emulsion required for intravenous delivery. Official information confirms that the drug's white appearance is a characteristic feature of this specialized lipid (fat-based) emulsion formulation.

Q: What if I drink alcohol the day before my procedure?

Regulatory labels classify alcohol as a CNS depressant which has an established additive effect with Propofol. This combination may significantly increase the risks of side effects, such as breathing difficulties and decreased blood pressure. Regulatory warnings indicate that recent alcohol use should be disclosed to the healthcare provider.

Q: What should I tell the doctor about other medications I am taking?

Regulatory documents strongly emphasize that Propofol interacts with many medications, especially other CNS depressants like opioids, sedatives, and inhalational agents. These combinations often require a lower Propofol dose and close medical monitoring. Regulatory documents emphasize the importance of disclosing all medicines to the healthcare professional due to the potential risk of excessive sedation or cardiorespiratory depression.

Q: Is Propofol addictive or habit-forming?

Although Propofol is currently not classified as a controlled substance under the US Controlled Substances Act, regulatory and safety organizations acknowledge its potential for abuse and addiction. This risk is specifically noted among healthcare professionals who may have easier access to the medication.

Q: How long does Propofol stay in a person's system?

Official pharmacological data confirms that Propofol has a very fast clearance rate from the body, which is why patients typically recover quickly. After a single injection, the primary effect usually lasts approximately three to five minutes before the drug is rapidly distributed away from the central nervous system.

Q: Are there alternatives to Propofol for short procedures?

Propofol is a standard agent for procedural sedation, but studies have been conducted comparing it to other options. Research reviews mention that other agents, including older sedatives and newer non-benzodiazepine alternatives, are available for short procedures. The final choice of agent is a clinical decision made by the prescribing healthcare professional.

Q: Why must Propofol only be administered by trained professionals?

Regulatory warnings highlight that Propofol administration carries the risk of rapid and profound changes in heart and breathing function, such as cardiorespiratory depression and transient apnea. Official guidelines state that administration should be performed by a trained professional whose sole responsibility is to monitor the patient and who is skilled in airway management and resuscitation techniques.

Q: Is it true that Propofol can cause vivid dreams or hallucinations when waking up?

Official regulatory data lists delirium or hallucinations as reported side effects, though they are considered rare. Reports of elation or euphoria upon waking are also noted in the list of common effects associated with the drug.

Q: Does Propofol affect blood sugar levels?

Propofol has been noted in clinical and regulatory reviews to affect glucose metabolism. In some cases, this can potentially lead to hyperglycemia, which is high blood sugar. Regulatory guidance states that blood glucose levels should be monitored during its administration, especially in diabetic patients.

Q: What kind of monitoring is done while a patient is receiving Propofol?

Regulatory requirements describe the specialized monitoring equipment that should be used by the professional administering the medication. This typically includes a cardiac monitor (ECG), pulse oximetry (to measure blood oxygen saturation), blood pressure equipment, and capnography (to monitor exhaled carbon dioxide).

Q: What type of procedures is Propofol most commonly used for?

Official documentation confirms that the drug is used for inducing and maintaining general anesthesia during surgery, as well as for continuous sedation of mechanically ventilated adults in the intensive care unit (ICU). It is also frequently utilized in dose-dependent sedation for short-term invasive procedures, such as endoscopy or colonoscopy.

Q: What is the difference between anesthesia and monitored anesthesia care when using Propofol?

Monitored Anesthesia Care (MAC) is a regulatory term describing a state of moderate to deep sedation where the patient is not completely unconscious, but they are monitored by an anesthesia professional. General Anesthesia, by contrast, is a deeper state where the patient is unconscious and may lose protective airway reflexes. Propofol can be used in clinical settings to achieve both states.

Q: Do studies show any link between Propofol and Post-Traumatic Stress Disorder (PTSD) from procedures?

Official information states that the long-term effects of Propofol are not fully established because research generally focuses on acute periods. However, some clinical studies have investigated a possible link, with some research indicating that early use of Propofol in emergency surgery for trauma may increase the risk of PTSD compared to other anesthetics.

How to Store and Dispose of Propofol

Propofol injectable emulsion must be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F and 77 F). The product must be protected from freezing to prevent the emulsion from breaking, and it should be kept in its original container and stored out of the sight and reach of children.

Due to the nature of the emulsion, the container is for single-patient use only. Any unused contents remaining in the ampule or vial must be discarded immediately after use. For disposal, unused or expired propofol should be handled according to local pharmaceutical waste regulations. Patients should use a drug take-back program if available or follow specific instructions to avoid disposal into wastewater.